“…The real incidence may be higher, considering that patients who deteriorated fastest could not be fully evaluated. HP was observed in the following types of cancer: non-small-cell lung carcinoma (8%-37%), melanoma (6%-34%), gastrointestinal (15%-21%), head and neck (9-18% and 29% in case of Squamous Cell Carcinoma), gynecological (16%), other lung (10-15%), cutaneous squamous cell carcinoma (9%), renal (5%-7%), colorectal (6%), urothelial (6%) [4,11,[32][33][34][35][36][37][38]. All the discussed studies pertained to PD-1/PD-L1-based immune checkpoint blockade.…”